Astria Therapeutics, Inc., a biopharmaceutical company specializing in therapies for allergic and immunologic diseases, has entered into a licensing agreement with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of navenibart in Japan. Navenibart is a long-acting investigational monoclonal antibody inhibitor of plasma kallikrein, currently in Phase 3 development for the preventative treatment of hereditary angioedema $(HAE)$. Under the agreement, Astria will receive an upfront payment of $16 million, with potential additional commercialization and sales milestones totaling $16 million. The company is also eligible for tiered royalties based on net sales, reaching up to 30%, and will receive partial reimbursement for Phase 3 costs. Kaken will support the ALPHA-ORBIT Phase 3 trial, handle regulatory submissions in Japan, and share in the costs of the Phase 3 program. No results from the Phase 3 trial have been presented as of the announcement.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。